Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys

Toxicological Sciences

Volumn 46, Issue 2, 1998, Pages 365-375

  Monteith, D K ^a   Geary, R S ^a   Leeds, J M ^a   Johnston, J ^a   Monia, B P ^a   Levin, A A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 69846A; ISIS 11061; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHOTRANSFERASE; RAF PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW DISEASE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HEPATOMEGALY; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTOSIS; LIVER CELL DAMAGE; MALE; MONKEY; MOUSE; NONHUMAN; THROMBOCYTOPENIA; TOXICITY TESTING; TOXICOKINETICS;

ANIMALIA; MURINAE;

EID: 0032430114     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1998.2527     Document Type: Article

References (36)

1. R.F. Branda A.L. Moore L. Mathews J.J. McCormack G. Zon Immune stimulation by an antisense oligomer complimentary to the rev gene of HIV-1 Biochem. Pharmacol. 45 1993 2037 2043
2. C.L. Cioffi M. Garay J.L. Johnston K. McGraw R.T. Boggs D. Hreniuk B.P. Monia Selective inhibition of A-raf and C-raf expression by antisense oligonucleotides in rat vascular smooth muscle cells: Role of A-raf and C-raf in serum-induced proliferation J. Pharmacol. Exp. Ther. 51 1997 383 389
3. 14 J. Pharmacol. Exp. Ther. 267 1993 1181 1190
4. S.T. Crooke Oligonucleotide Therapeutics Burger's Medicinal Chemistry and Drug Discovery 1995 Wiley New York p. 863–900
5. S.T. Crooke New drugs and changing disease paradigms Nature Biotech. 14 1996 238 241
6. N.M. Dean R. McKay Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides Proc. Natl. Acad. Sci. USA 91 1994 11762 11766
7. T. Diamantstein E. Blistein-Willinger Specific binding of poly (I)–poly (C) to the membrane of murine B lymphocyte subsets Eur. J. Immunol. 8 1978 896 899
8. T. Diamantstein B. Wagner I. Beyse M.V. Odenwald G. Schultz Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice Eur. J. Immunol. 1 1971 340 343
9. W.M. Galbraith W.C. Hobson P.C. Giclas P.J. Schechter S. Agrawal Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey Antisense Res. Dev. 4 1994 201 206
10. R.S. Geary J.M. Leeds J. Fitchett T. Burckin L. Troung C. Spainhour M. Creek A.A. Levin Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression Drug Metab. Dispos. 25 1997 1272 1281
11. S.P. Henry H. Bolte C. Auletta D.J. Kornbrust Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys Toxicology 120 1997 145 155
12. S.P. Henry P.C. Giclas J. Leeds M. Pangburn C. Auletta A.A. Levin D.J. Kornbrust Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action J. Pharmacol. Exp. Ther. 281 1997 810 816
13. S.P. Henry L.R. Grillone J.L. Orr R.H. Brunner D.J. Kornbrust Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague–Dawley rats Toxicology 116 1997 77 88
14. S.P. Henry D. Monteith A.A. Levin Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides Anti-Cancer Drug Des. 12 1997 395 408
15. S.P. Henry W. Novotny J. Leeds C. Auletta D.J. Kornbrust Inhibition of coagulation by a phosphorothioate oligonucleotide Antisense Nucleic Acid Drug Dev. 7 1997 503 510
16. S.P. Henry J. Taylor L. Midgley A.A. Levin D.J. Kornbrust Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice Antisense Nucleic Acid Drug Dev. 7 1997 473 481
17. J. Holmlund J. Nmunaitis J. Schiller A. Dorr D. Kisner Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer Proceedings of the American Society of Clinical Oncology 1998
18. E.R. Homan R.P. Zendzian L.D. Schott H.B. Levy R.H. Adamson Studies on poly I: C toxicity in experimental animals Toxicol. Appl. Pharmacol. 23 1972 579 588
19. A.M. Krieg A.-K. Yi S. Matson T.J. Waldschmidt G.A. Bishop R. Teasdale G.A. Koretzky D.M. Klinman CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
20. E. Kuramoto O. Yano Y. Kimura M. Baba T. Makino S. Yamamoto T. Yamamoto T. Kataoka T. Tokonaga Oligonucleotide sequences required for natural killer cell activation Jpn. J. Cancer Res. 83 1992 1128 1131
21. J.M. Leeds M.J. Graham L. Truong L.L. Cummins Quantitation of phosphorothioate oligonucleotides in human plasma Anal. Biochem. 235 1996 36 43
22. L. Ma F. Calvo Recent status of the antisense oligonucleotide approaches in oncology Fundam. Clin. Pharmacol. 10 1996 97 115
23. S. Mandiyan C. Schumacher C. Cioffi H. Sharif A. Yuryev R. Lappe B. Monia S. Hanson S. Goff L. Wennogle Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides Antisense Nucleic Acid Drug Dev. 7 1997 539 548
24. K.W. McIntyre K. Lombard-Gilloly J.R. Perez C. Kunsch U.M. Sarmiento J.D. Larigan K.T. Landreth R. Narayanan A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation Antisense Res. Dev. 3 1993 309 322
25. B.P. Monia J.F. Johnston T. Geiger M. Muller D. Fabbro Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C- raf Nature Med. 2 1996 668 675
26. B.P. Monia J.F. Johnston H. Sasmor L.L. Cummins Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras J. Biol. Chem. 24 1996 14533 14540
27. D.K. Monteith S.P. Henry R.B. Howard S. Flournoy A.A. Levin C.F. Bennett S.T. Crooke Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents Anti-Cancer Drug Des. 12 1997 421 432
28. P.J. O'Dwyer J.P. Stevenson M. Gallagher E. Mitchell D. Friedland L. Rose A. Cassella J. Holmlund N. Dean A. Dorr R. Geary K.-S. Yao Phase I/pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A) Proceedings of the American Society of Clinical Oncology 1998
29. D.S. Pisetsky C.F. Reich Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus Life Sci. 54 1994 101 107
30. U.M. Sarmiento J.R. Perez J.M. Becker N. Ramaswamy In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice Antisense Res. Dev. 4 1994 99 107
31. S. Shimada O. Yano T. Tokunaga In vivo Jpn. J. Cancer Res. 77 1986 808 816
32. T. Tokunaga S. Yamamato K. Namba A synthetic single-stranded DNA, poly(dG,dC), induces interferon-a/B and -g, augments natural killer activity, and suppresses tumor growth Jpn. J. Cancer Res. 79 1988 682 686
33. T. Yamamoto S. Yamamoto T. Kataoka T. Tokunaga Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length Antisense Res. Dev. 4 1994 119 122
34. T. Yazaki S. Ahmad A. Chahlavi E. Zylber-Katz N.M. Dean S.D. Rabkin R.L. Martuza R.I. Glazer Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide Mol. Pharmacol. 50 1996 236 242
35. Q. Zhao J. Temsamani P.L. Iadarola Z. Jiang S. Agrawal Effect of different chemically modified oligodeoxynucleotides on immune stimulation Biochem. Pharmacol. 51 1995 173 182
36. Q. Zhao J. Temsamani R.-Z. Zhou S. Agrawal Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice Antisense Nucleic Acid Drug Dev. 7 1997 495 502